EA201992852A1 - Схема дозирования тезетаксела и капецитабина - Google Patents

Схема дозирования тезетаксела и капецитабина

Info

Publication number
EA201992852A1
EA201992852A1 EA201992852A EA201992852A EA201992852A1 EA 201992852 A1 EA201992852 A1 EA 201992852A1 EA 201992852 A EA201992852 A EA 201992852A EA 201992852 A EA201992852 A EA 201992852A EA 201992852 A1 EA201992852 A1 EA 201992852A1
Authority
EA
Eurasian Patent Office
Prior art keywords
capetsitabine
tesetaxel
dosage
diagram
cancer
Prior art date
Application number
EA201992852A
Other languages
English (en)
Inventor
Томас Вей
Кевин Танг
Стью Кролл
Джон Г. Лемки
Стивен Пфайффер
Джефф Васирка
Original Assignee
Одонейт Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Одонейт Терапьютикс, Инк. filed Critical Одонейт Терапьютикс, Инк.
Publication of EA201992852A1 publication Critical patent/EA201992852A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предложены способы лечения пациентов с раком, таким как метастатический рак молочной железы, включающие введение пациенту тезетаксела и капецитабина.
EA201992852A 2017-06-02 2018-06-01 Схема дозирования тезетаксела и капецитабина EA201992852A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514483P 2017-06-02 2017-06-02
PCT/US2018/035653 WO2018223029A1 (en) 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine

Publications (1)

Publication Number Publication Date
EA201992852A1 true EA201992852A1 (ru) 2020-03-27

Family

ID=64455637

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992852A EA201992852A1 (ru) 2017-06-02 2018-06-01 Схема дозирования тезетаксела и капецитабина

Country Status (14)

Country Link
US (1) US20200179427A1 (ru)
EP (1) EP3630091A4 (ru)
JP (1) JP2020522568A (ru)
KR (1) KR20200014880A (ru)
CN (1) CN111032035A (ru)
AU (1) AU2018275122A1 (ru)
BR (1) BR112019025164A2 (ru)
CA (1) CA3065783A1 (ru)
EA (1) EA201992852A1 (ru)
IL (1) IL270973A (ru)
MA (1) MA50039A (ru)
MX (1) MX2019014489A (ru)
TW (1) TW201902473A (ru)
WO (1) WO2018223029A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210386720A1 (en) * 2018-10-17 2021-12-16 Odonate Therapeutics, Inc. Methods of treating cns tumors with tesetaxel
TW202112364A (zh) * 2019-08-16 2021-04-01 美商蜻蛉治療股份有限公司 投與替司他賽(tesetaxel)與cyp3a4誘導劑之糖皮質素之方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168451A1 (en) * 2015-04-14 2016-10-20 Merrimack Pharmaceuticals, Inc. Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment

Also Published As

Publication number Publication date
CN111032035A (zh) 2020-04-17
EP3630091A4 (en) 2021-03-10
EP3630091A1 (en) 2020-04-08
KR20200014880A (ko) 2020-02-11
TW201902473A (zh) 2019-01-16
CA3065783A1 (en) 2018-12-06
BR112019025164A2 (pt) 2020-06-16
AU2018275122A1 (en) 2019-12-19
JP2020522568A (ja) 2020-07-30
US20200179427A1 (en) 2020-06-11
MA50039A (fr) 2020-07-08
WO2018223029A1 (en) 2018-12-06
MX2019014489A (es) 2020-08-17
IL270973A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2023014569A (es) Anticuerpos anti-sirpa.
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201692472A1 (ru) Соединения для лечения рака мозга
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
EA202090270A1 (ru) Новые замещенные производные ксантина
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение